Watchdog says expensive cancer drugs not delivering

Watchdog says expensive cancer drugs not delivering
A study has found that 57 per cent of new cancer drugs in Europe lack clear evidence that they extend or improve patients’ lives Pic: Shutterstock

Value for money criteria met by only one of 20 new drugs that had an initial asking price of €500 million

Just one of 20 new cancer drugs examined by the state’s medicines watchdog was considered value for money, according to a new assessment by the body.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events
  • Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
  • Access to The Business Post's extensive archive​

Related Articles

More from The Business Post